Assessing the Anti-Inflammatory Effects of an Orally Dosed Enzymatically Liberated Fish Oil in a House Dust Model of Allergic Asthma
Journal article, Peer reviewed
Published version
![Thumbnail](/bora-xmlui/bitstream/handle/11250/3035084/biomedicines-10-02574.pdf.jpg?sequence=6&isAllowed=y)
Åpne
Permanent lenke
https://hdl.handle.net/11250/3035084Utgivelsesdato
2022-10-14Metadata
Vis full innførselSamlinger
- Department of Clinical Medicine [2086]
- Registrations from Cristin [10237]
Sammendrag
Eosinophils are a major driver of inflammation in a number of human diseases, including asthma. Biologic therapies targeting IL-5 have enabled better control of severe eosinophilic asthma, but no such advances have been made for enhancing the control of moderate asthma. However, a number of moderate asthma sufferers remain troubled by unresolved symptoms, treatment side effects, or both. OmeGo, an enzymatically liberated fish oil, has demonstrated antioxidant and anti-inflammatory properties including the reduction of eosinophilia. A house dust mite model of induced asthma in mice was utilized in this study, and OmeGo showed a significant reduction in eosinophilic lung and systemic inflammation and reduced lung remodelling compared to cod liver oil. The CRTH2 antagonist fevipiprant showed an anti-inflammatory profile similar to that of OmeGo. OmeGo has the potential to be a pragmatic, cost-effective co-treatment for less severe forms of eosinophilic asthma. Proof-of-concept studies are planned.